Close Menu

BMS

According to a team led by researchers at Plymouth University, there are significant flaws in the standard cognitive test used to diagnose and evaluate Alzheimer's disease patients, which could be hampering efforts to develop treatments and biomarkers for the disease.

Testing for gene mutations that hinder the ability of colorectal cancer patients to respond to anti-EGFR drugs is a cost-effective way of administering such pricey treatments, according to

Just days before they were scheduled to go to trial, Alnylam Pharmaceuticals and Tekmira Pharmaceuticals announced that they have hammered out a settlement to their protracted patent-infringement and technology-misappropriation lawsuits.

Despite its relatively low profile since it kicked off its third phase last spring, the Broad Institute's RNAi Consortium is proceeding apace, although its mission has expanded beyond its initial focus of just RNAi.

Quest Diagnostics has begun offering a test for measuring free epidermal growth factor receptor using Somalogic's aptamer-based Somamer technology.

NEW YORK (GenomeWeb News) – Life Technologies said today that it would collaborate with Bristol-Myers Squibb to develop companion diagnostics. Initially, the companies will partner on an oncology project with the option to expand collaborative efforts across a range of disease areas.

NEW YORK (GenomeWeb News) – Saladax today said it has expanded its relationship with Bristol-Myers Squibb and entered into a Master Early Development Collaboration Agreement.

Opko Health last week presented data at the Alzheimer's Association International Conference in Vancouver demonstrating that its antibody-based Alzheimer's diagnostic identified cases of the disease with 100 percent specificity in a set of 36 autopsy-confirmed plasma samples.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.